Nacubactam clinical trials
Also written RO7079901.
How each study uses nacubactam is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Hoffmann-La Roche (4) · Meiji Seika Pharma Co., Ltd. (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses nacubactam is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant EnterobacteralesCompletedPhase 3Meiji Seika Pharma Co., Ltd.NCT05905055Written as co-administration of cefepime and nacubactam
- Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated PyelonephritisCompletedPhase 3Meiji Seika Pharma Co., Ltd.NCT05887908Written as co-administration of cefepime and nacubactam
- A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract InfectionCompletedPhase 1Hoffmann-La RocheNCT03174795Written as RO7079901
- A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy ParticipantsCompletedPhase 1Hoffmann-La RocheNCT03182504Written as nacubactam
- A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901CompletedPhase 1Hoffmann-La RocheNCT02975388Written as RO7079901
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT02972255Written as RO7079901
- A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595CompletedPhase 1Meiji Seika Pharma Co., Ltd.NCT02134834Written as OP0595
Codes
What other systems call nacubactam · ClinicalTrials.gg INT000482
- MeSH (NLM) C000608518nacubactamOne source NLM
- UNII (FDA) 832O37V7MZNACUBACTAMConfirmed FDA, NLM, Wikidata
- Wikidata Q27269383nacubactamConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175153NacubactamOne source FDA
- DrugBank DB15353One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608518 | nacubactam | One source NLM |
| UNII (FDA) | 832O37V7MZ | NACUBACTAM | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27269383 | nacubactam | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175153 | Nacubactam | One source FDA |
| DrugBank | DB15353 | — | One source Wikidata |
Also registered as nacubactam monohydrate (UNII NRY8741D3C).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.